Clinical Trial Update: Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors [Phase 3]

View source ↗

Summary

A Phase III trial comparing palbociclib with endocrine therapy versus capecitabine in HR+/HER2- metastatic breast cancer with aromatase inhibitor resistance has…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (Xeloda) (Capecitabine)
• Palbociclib (Ibrance) (palbociclib)

Snippet

Sponsor: Spanish Breast Cancer Research Group | Conditions: Metastatic Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2024-09-25